drugset
drugset / Trial / NCT05749848

A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants

NCT05749848 ↗

Phase 1 Completed 8 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate how much of the study drug (LY3372689), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.

Timeline

Start
2023-02-24
Primary completion
2023-04-18
Completion
2023-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ceperognastat Small molecule — Oral

Indications

No indication recorded.